The galactomannan antigen test for Aspergillus is a blood (or sometimes bronchoalveolar lavage) assay that detects galactomannan, a polysaccharide component of the cell wall of Aspergillus fungi. It is needed to aid in the early diagnosis of invasive aspergillosis, a serious and potentially life-threatening infection that mainly affects immunocompromised patients, such as those with hematologic malignancies or transplant recipients, allowing timely antifungal treatment when culture or imaging findings may be delayed or inconclusive.
Immunocompromised patients, especially those with hematologic malignancies, transplant recipients, or individuals on high-dose corticosteroids or other immunosuppressive therapies.
A positive result supports the possibility of invasive aspergillosis, especially when combined with clinical symptoms, risk factors, and imaging findings. It does not confirm the diagnosis by itself.
A negative result makes invasive aspergillosis less likely but does not completely rule it out. Repeat testing may be recommended if clinical suspicion remains high.
Certain antibiotics (e.g., piperacillin-tazobactam, amoxicillin-clavulanate), other fungal infections, some intravenous solutions, or cross-reactivity with other molds can occasionally produce false-positive results.
Use of mold-active antifungal prophylaxis or therapy, low fungal burden, or testing too early in the course of infection may lead to false-negative results.